<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - MANNITOL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>MANNITOL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#preTreatmentScreening" data-toggle="tab">Pre-treatment screening</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cerebral oedema</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.25&#8211;2 g/kg, repeated if necessary, to be administered over 30-60 minutes, dose may be repeated 1&#8211;2 times after 4&#8211;8 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Raised intra-ocular pressure</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.25&#8211;2 g/kg, repeated if necessary, to be administered over 30&#8211;60 minutes, dose may be repeated 1&#8211;2 times after 4&#8211;8 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of cystic fibrosis as an add-on therapy to standard care</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of powder</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Maintenance 400 mg twice daily, an initiation dose assessment must be carried out under medical supervision, for details of the initiation dose regimen, consult product literature.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Manufacturer advises avoid unless essential&#8212; no information available.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Manufacturer advises avoid.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Use with caution in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> cough, haemoptysis, headache, pharyngolaryngeal pain, throat irritation, vomiting, wheezing,
              </p>
              <p>
                <strong>uncommon:</strong> acne, arthralgia, bronchospasm, dizziness, dysphonia, dyspnoea, ear pain, eructation, flatulence, gastro-oesophageal reflux disease, glossodynia, hyperventilation, influenza-like illness, malaise, nausea, oral candidiasis, pharyngitis, pruritus, pyrexia, rash, rhinorrhoea, stomatitis, transient insomnia, electrolyte imbalance, fluid imbalance, hypotension, thrombophlebitis,
              </p>
              <p>
                <strong>rare:</strong> anaphylaxis, arrhythmia, blurred vision, chest pain, chills, convulsions, cramp, dehydration, dizziness, dry mouth, fever, focal osmotic nephrosis, headache, hypersensitivity reactions, hypertension, nausea, oedema, pulmonary oedema, raised intracranial pressure, rhinitis, skin necrosis, thirst, urinary retention, urticaria, vomiting,
              </p>
              <p>
                <strong>veryRare:</strong> acute renal failure, congestive heart failure,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For mannitol 20%, an in-line filter is recommended (15-micron filters have been used).</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>The dose should be administered 5&#8211;15 minutes after a bronchodilator and before physiotherapy; the second daily dose should be taken 2&#8211;3 hours before bedtime.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Patients or carers should be given advice on how to administer mannitol inhalation powder.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA266</h3>
              <p outputclass="specificity">When used by <ph outputclass="route">inhalation</ph> </p> <p outputclass="title">Mannitol dry powder for inhalation for treating cystic fibrosis (November 2012)</p> <p>Mannitol dry powder for inhalation is recommended as an option for treating cystic fibrosis in adults:</p> <ul> <li>who cannot use dornase alfa (rhDNase) because of ineligibility, intolerance or inadequate response to dornase alfa (rhDNase), <b>and</b> </li> <li>whose lung function is rapidly declining (forced expiratory volume in 1 second decline greater than 2% annually), <b>and</b> </li> <li>for whom other osmotic agents are not considered appropriate.</li> </ul><xref format="html" href="http://www.nice.org.uk/TA266">www.nice.org.uk/TA266</xref>
                <a href="http://www.nice.org.uk/TA266" target="_blank">www.nice.org.uk/TA266</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>When used by inhalation:</strong>
            asthma
          </li>
          <li>
              <strong>When used by inhalation:</strong>
            haemoptysis
          </li>
          <li>
              <strong>With intravenous use:</strong>
            extravasation causes inflammation and thrombophlebitis
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Monitor fluid and electrolyte balance, serum osmolality, and cardiac, pulmonary and renal function.</p>
            </section>
      </section>






      <section class="tab-pane" id="preTreatmentScreening">
        <h2>Pre-treatment screening</h2>

            <section class="preTreatmentScreening">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Patients must be assessed for bronchial hyperresponsiveness to inhaled mannitol before starting the therapeutic dose regimen; an initiation dose assessment must be carried out under medical supervision&#8212;for details of the initiation dose regimen, consult product literature.</p>
            </section>
            <section class="preTreatmentScreening">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Assess cardiac function before treatment.</p>
            </section>
      </section>





      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of MANNITOL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for infusion,
            infusion,
            oral solution,

            <div id="PHP75094"><a href="../medicinalForm/PHP75094.html" data-target="#PHP75094" data-action="load">Infusion</a></div>
            <div id="PHP75100"><a href="../medicinalForm/PHP75100.html" data-target="#PHP75100" data-action="load">Inhalation powder</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
